Scienture Holdings, Inc. (SCNX)
About Scienture Holdings, Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $431.6K
- Net income
- -$41.5M
- Total assets
- $84.2M
- Market cap
- $14.6M
- Gross margin
- 76.8%
- Operating margin
- -9867.9%
- Net margin
- -9618.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $431.6K
- Cost of revenue
- $100.1K
- Gross profit
- $331.5K
- Operating expenses
- $42.9M
- Operating income
- -$42.6M
- Income tax
- -$2.0M
- Net income
- -$41.5M
- EPS (basic)
- $-2.70
- EPS (diluted)
- $-2.70
Balance sheet
- Total assets
- $84.2M
- Current assets
- $7.9M
- Total liabilities
- $14.1M
- Current liabilities
- $2.7M
- Shareholders’ equity
- $70.1M
Cash flow
- Operating cash flow
- -$13.4M
- Investing cash flow
- -$6.4M
- Financing cash flow
- $19.7M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $14.6M
- EPS (diluted)
- $-2.7
- Shares outstanding
- 39.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 22, 2008
Scienture Holdings, Inc. (SCNX) Stock Price
- Reported a net loss of $41.5M in FY2025.
- Revenue grew 216% from FY2024 to FY2025.
- Gross margin of 76.8%, net margin -9618.0%.
- Trading 86% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Scienture Holdings, Inc..
Write a review
News about Scienture Holdings, Inc.
News & sentiment via Polygon.io
Scienture Holdings, Inc.: frequently asked questions
Is Scienture Holdings, Inc. an American company?
Scienture Holdings, Inc. is a US-based company headquartered in Commack, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Scienture Holdings, Inc. headquartered?
Scienture Holdings, Inc. is headquartered in Commack, New York, United States.
Is Scienture Holdings, Inc. publicly traded?
Yes — Scienture Holdings, Inc. is a publicly traded company. Its stock trades under the ticker symbol SCNX on the NASDAQ.
What does Scienture Holdings, Inc. do?
Scienture Holdings, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
